Cargando…
Clinical value of matrix metalloproteinase-2 and -9 in ultrasound-guided radiofrequency ablation treatment for papillary thyroid carcinoma
OBJECTIVE: This study aimed to investigate serum matrix metalloproteinase (MMP)-2 and MMP-9 levels in patients with papillary thyroid carcinoma (PTC). METHODS: Forty-one patients with PTC undergoing ultrasound-guided radiofrequency ablation (RFA) and 56 controls were included. Serum MMP-2 and MMP-9...
Autores principales: | Pan, Qunyan, Yuan, Tao, Ding, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418228/ https://www.ncbi.nlm.nih.gov/pubmed/32772889 http://dx.doi.org/10.1177/0300060520917581 |
Ejemplares similares
-
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer
por: Radisky, Evette S., et al.
Publicado: (2017) -
Effect of chronic lymphocytic thyroiditis on the efficacy and safety of ultrasound‐guided radiofrequency ablation for papillary thyroid microcarcinoma
por: Zhang, Yan, et al.
Publicado: (2019) -
Radiofrequency Ablation of Papillary Thyroid Microcarcinomas
por: Rangel, Leonardo Guimarães, et al.
Publicado: (2022) -
Correlation Between the Expression of Matrix Metalloproteinase-9, Matrix Metalloproteinase-13, Tissue Inhibitor of Metalloproteinases-1, p16 and Differentiation of Head and Neck Squamous Cell Carcinoma: A Prospective Observational Study
por: Soni, Kapil, et al.
Publicado: (2021) -
Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis
por: Liu, Xingkai, et al.
Publicado: (2019)